


Jane Mitchell 01 Dec 1974



Care Summary

Last Modified 03 Dec 2021

My Health



My Cancer

- **10 Sept 2019 (Latest)**
Diagnosis (Current, Primary): Glioblastoma
Stage/Grade: WHO Central Nervous System Grade 4
Location(s): Brain, Right frontoparietal lobe

Biomarkers

DATE	GENE	ALTERATION
06 Jul 2021	Tumor Mutational Burden	1.6 mutations/MB
06 Jul 2021	MGMT	Unmethylated
06 Jul 2021	Ki-67	14.8%
06 Jul 2021	GFAP	Positive
06 Jul 2021	EGFR	Positive
06 Jul 2021	p53	Nuclear staining in a few scattered cells
06 Jul 2021	EGFR	Ser768Ile

Jane Mitchell 01 Dec 1974

06 Jul 2021	TERT	C228T
06 Jul 2021	MSI	Negative
06 Jul 2021	IDH-1 R132H	Negative
10 Sept 2019	MGMT	Unmethylated
10 Sept 2019	EGFR	Missense mutation
10 Sept 2019	Ki-67	50%
10 Sept 2019	ATRX	Preserved in majority of tumor cells
10 Sept 2019	1p/19q co-deletion	Negative
10 Sept 2019	p53	<5%
10 Sept 2019	IDH2	Negative
10 Sept 2019	IDH1 R132H	Negative

Current Treatments

- **Unspecified date**
Cannabidiol
- **03 Oct 2021**
Lomustine
200mg every 6 weeks
- **01 Oct 2021**
Valacyclovir
500mg BID
- **01 Oct 2021**
Bevacizumab
15 mg/kg every 3 weeks
- **15 May 2021**
Metformin

Jane Mitchell 01 Dec 1974

500 mg

- **15 May 2021**
Atorvastatin
40 mg
- **15 May 2021**
Doxycycline
100mg QD 3 months on 30 days off
- **15 May 2021**
Mebendazole
200mg QD

Historical Surgeries and Therapies

- **02 Sept 2021 - 06 Sept 2021**
Temozolomide
150 mg/m²; cycle 13, stopped due to rapid tumor growth
- **09 Jul 2021 - 20 Jul 2021**
Dexamethasone
2mg BID
- **06 Jul 2021 - 06 Jul 2021**
Resection
Right frontoparietal lobe
- **28 Jan 2020 - 12 Jan 2021**
Temozolomide
150 mg/m²; 12 cycles
- **30 Oct 2019 - 11 Dec 2019**
Radiation Therapy
Brain
- **30 Oct 2019 - 11 Dec 2019**
Temozolomide
- **15 Oct 2019 - 17 Apr 2020**
Bevacizumab
10 mg/kg; NCT01269853
- **12 Sept 2019 - 12 Oct 2019**
Dexamethasone
2mg



Jane Mitchell 01 Dec 1974



10 Sept 2019 - 10 Sept 2019

Gross Total Resection

Right frontoparietal lobe